AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

DIMERIX LTD

0.225

-0.010-4.26%

Volume:402.28K

Turnover:91.13K

Market Cap:135.09M

PE:-4.53

High:0.230

Open:0.230

Low:0.225

Close:0.235

52wk High:0.665

52wk Low:0.157

Shares:600.40M

Float Shares:467.70M

Volume Ratio:0.81

T/O Rate:0.09%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.050

EPS(LYR):-0.050

ROE:-594.54%

ROA:-29.36%

PB:-9.15

PE(LYR):-4.53

Loading ...

Overview Company News Filings

Dimerix - Trading Halt Requested Pending Out-Licensing Agreement Announcement

THOMSON REUTERS

Dimerix's Potential Non-Dilutive Funding May Lead to Ongoing Phase Three Trial Being Fully Funded, Euroz Hartleys Says

MT Newswires Live

BLINDED ASSESSMENT OF ACTION3 STATISTICAL ASSUMPTIONS COMPLETE

Dimerix Poised to Benefit From US FDA's Approval of Travere Therapeutics' Kidney Disorder Drug, Euroz Hartleys Says

MT Newswires Live

Dimerix Sees No Impact From US Pharma Tariffs, Says Euroz Hartleys

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/DXB.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"DXB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","market":"AU","secType":"STK","nameCN":"DIMERIX LTD","latestPrice":0.225,"timestamp":1790921520000,"preClose":0.235,"halted":0,"volume":402282,"delay":0,"changeRate":-0.042553191489361625,"nameEN":"DIMERIX LTD","floatShares":467696880,"shares":600396776,"eps":-0.0497,"marketStatus":"Closed","change":-0.01,"latestTime":"10-02 16:12:00 AEST","open":0.23,"high":0.23,"low":0.225,"amount":91128,"amplitude":0.021277,"askPrice":0.23,"askSize":2000,"bidPrice":0.225,"bidSize":229508,"shortable":3,"etf":0,"ttmEps":-0.0497,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791154800000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.235,"openAndCloseTimeList":[[1790899200000,1790920800000]],"volumeRatio":0.812026,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"DXB.AU","preClose":0.235,"auctionPrice":0.225,"auctionVolume":166282,"auctionTime":1790921400253,"referencePrice":0.225,"referenceTime":1790937003087,"auction":3,"marketStatus":"盘后竞价","timestamp":1790921400253}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","floatShares":467696880,"roa":"-29.36%","roe":"-594.54%","lyrEps":-0.0497,"volumeRatio":0.812026,"shares":600396776,"dividePrice":0,"high":0.23,"amplitude":0.021277,"preClose":0.235,"low":0.225,"week52Low":0.157,"pbRate":"-9.15","psRate":"21.26","week52High":0.665,"institutionHeld":0,"latestPrice":0.225,"committee":0.982722,"eps":-0.0497,"divideRate":0,"volume":402282,"delay":0,"ttmEps":-0.0497,"open":0.23,"prevYearClose":0.55,"prevWeekClose":0.225,"prevMonthClose":0.23,"prevQuarterClose":0.23,"fiveDayClose":0.225,"twentyDayClose":0.285,"sixtyDayClose":0.24,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DXB.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DXB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DXB.AU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2643285092","title":"Dimerix - Trading Halt Requested Pending Out-Licensing Agreement Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2643285092","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643285092?lang=en_us&edition=fundamental","pubTime":"2026-06-15 07:14","pubTimestamp":1781478847,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260614:nFWN42K0NK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7508","BK7067","DXB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632699919","title":"Dimerix's Potential Non-Dilutive Funding May Lead to Ongoing Phase Three Trial Being Fully Funded, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2632699919","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632699919?lang=en_us&edition=fundamental","pubTime":"2026-05-01 10:45","pubTimestamp":1777603552,"startTime":"0","endTime":"0","summary":"Dimerix's  potential access to $50 million in non-dilutive funding could lead to it having up to AU$96.6 million in combined cash and non-dilutive funding available, which would be sufficient to fully fund the ongoing phase three trial and dispel any near-term capital raising risk, Euroz Hartleys said in a note on Thursday.It indicated this would not be traditional debt funding, but is rather repayable from future milestone payments and/or royalties.The commercial opportunity remains significant and unchanged, Euroz Hartleys added.The investment firm maintained its speculative buy rating on Dimerix with a price target of AU$1.35 per share.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","DBB","DXB.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2630234053","title":"BLINDED ASSESSMENT OF ACTION3 STATISTICAL ASSUMPTIONS COMPLETE","url":"https://stock-news.laohu8.com/highlight/detail?id=2630234053","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630234053?lang=en_us&edition=fundamental","pubTime":"2026-04-28 10:17","pubTimestamp":1777342620,"startTime":"0","endTime":"0","summary":"An external statistical blinded review of ACTION3 data has achieved its objective by confirming that the study remains appropriately statistically powered  to demonstrate a treatment effect for the primary study endpoint of proteinuria; meaning that if DMX-200 continues to reduce proteinuria in trial patients as anticipated, then there is a >90% chance that the study will successfully show a statistically significant proteinuria treatment effect at the trial's conclusion. To maximise the likelihood of a successful study outcome and regulatory success, Dimerix and its commercialisation partners will continue the ACTION3 Phase 3 Study to the final proteinuria endpoint. As previously announced, the FDA has agreed that proteinuria is an appropriate endpoint for full regulatory approval for DMX-200 in ACTION3. Evidence from the PARASOL working group, together with the recent FDA approval of an FSGS therapy in the US based on the proteinuria endpoint, further supports proteinuria as the prim","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/blinded-assessment-of-action3-statistical-assumptions-complete-302755001.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARB","DXB.AU","BK7051","BK7508","ARB.AU","FSGS","BK7501","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627999814","title":"Dimerix Poised to Benefit From US FDA's Approval of Travere Therapeutics' Kidney Disorder Drug, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2627999814","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627999814?lang=en_us&edition=fundamental","pubTime":"2026-04-14 12:01","pubTimestamp":1776139286,"startTime":"0","endTime":"0","summary":"Dimerix (ASX:DXB) is poised to benefit from the US Food and Drug Administration's recent approval of Travere Therapeutics' sparsentan drug to treat focal segmental glomerulosclerosis, a rare kidney di","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","BK4007","BK7508","DXB.AU","BK7067","BK4139","BK4585","LENZ","BK7501","BK4588","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625399752","title":"Dimerix Sees No Impact From US Pharma Tariffs, Says Euroz Hartleys","url":"https://stock-news.laohu8.com/highlight/detail?id=2625399752","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625399752?lang=en_us&edition=fundamental","pubTime":"2026-04-08 13:55","pubTimestamp":1775627705,"startTime":"0","endTime":"0","summary":"Dimerix  is protected from recent US pharmaceutical tariff changes due to its out-licensing model, Euroz Hartleys said in a note on Tuesday.The Trump administration imposed tariffs on imported patented pharmaceuticals under Section 232 of the Trade Expansion Act, citing national security risks in the pharmaceutical supply chain.The standard tariffs are 100%, with reduced rates of 15% for the European Union, Japan, South Korea, Switzerland, and Liechtenstein, and 10% for the United Kingdom. The administration is allowing a transition period of 120 days for large companies and 180 days for small companies before these tariffs take effect.Euroz Hartleys notes that the company's out-licensing model shields it from higher manufacturing costs, with royalties and milestone payments tied to revenue rather than production expenses, meaning the US tariffs are not expected to affect the company's financial forecasts.Euroz Hartleys maintained its speculative buy rating on Dimerix with a price targ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","DXB.AU","BK7501","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":45,"code":"91000000","status":"200"}]}}